{
    "ASSERTIONS": {
        "id": 70,
        "context": null,
        "description": "ETS fusions did not have a better response to AR suppression and PARP inhibition.",
        "disease": {
            "name": "Prostate Adenocarcinoma",
            "oncotree_code": "PRAD",
            "oncotree_term": "Prostate Adenocarcinoma"
        },
        "therapy_name": "Veliparib",
        "therapy_type": "Targeted therapy",
        "clinical_significance": null,
        "predictive_implication": "Clinical trial",
        "favorable_prognosis": null,
        "created_on": "11/04/21",
        "last_updated": "2019-01-29",
        "submitted_by": "breardon@broadinstitute.org",
        "validated": true,
        "source_ids": 43,
        "variant": {
            "id": 67,
            "feature_type": "rearrangement",
            "gene1": "TMPRSS2",
            "gene2": "ERG",
            "locus": null,
            "rearrangement_type": "Fusion",
            "feature": "TMPRSS2--ERG Fusion"
        }
    },
    "SOURCES": {
        "id": 43,
        "type": "Journal",
        "doi": "10.1200/JCO.2017.75.7310",
        "nct": "NCT01576172",
        "pmid": 29261439,
        "url": "https://doi.org/10.1200/JCO.2017.75.7310",
        "citation": "Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."
    },
    "VARIANTS": {
        "id": 67,
        "feature_type": "rearrangement",
        "gene1": "TMPRSS2",
        "gene2": "ERG",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "TMPRSS2--ERG Fusion"
    }
}